Oracle growth initiative gives CROs access to innovative Clinical One platform to spur adoption and improve trial efficienciesAustin, Texas—February 2, 2023
While increased investment in pharmaceutical research and development is creating more opportunities for Contract Research Organizations (CROs), many are struggling to keep pace with competitive pressures, changing market requirements, and a lack of skilled talent. To help CROs meet these challenges, Oracle introduced its CRO Growth Initiative in August 2022. The global program offers CROs no-obligation access to Oracle Clinical One, a leading eClinical platform, for non-production purposes. Through the program, CROs can evaluate, familiarize, train, and enable their users with the technology and demonstrate the power of Clinical One to potential sponsors. Already, hundreds of CRO professionals have taken advantage of the program’s accelerator that provides go-to-market benefits, technical enablers, and incentives all constructed to help them to get trials up and running faster.
“We’re excited to join the CRO Growth Initiative,” said Ivan Pessotto, Senior Director, Clinical Data Management, Everest Clinical Research. “With no risk, trials credits, and additional support, it just made good business sense.”
“The CRO Growth Initiative is a way for CRO professionals to use Clinical One in a sandbox environment and experience its value firsthand,” said Henry McNamara, general manager and senior vice president, Oracle Health Sciences. “This helps accelerate a CRO’s ability to adopt the technology and ultimately provide sponsors with the assurance that their trials will run on a leading, efficient, and innovative platform – Clinical One.”
According to Frost & Sullivan, the CRO market is estimated to garner revenue of $63.83 billion by 2024, up from $43.03 billion in 2019, at a compound annual growth rate (CAGR) of 8.2%. Yet, recent market consolidation and siloed technology has hindered CRO success, especially amongst smaller organizations.
“As a growing CRO, we are excited that Oracle, Oracle’s CRO Growth Initiative, and Clinical One are supporting our business goals to grow and address new markets,” said Antonio Berlanga, CEO, Sermes CRO.
Clinical One is the only truly unified eClinical platform that harmonizes data, streamlines workflow, and saves significant time from study startup to study closeout. It enables stakeholders to have quick and easy access to the data needed to support critical decision-making, patient safety, and study oversight. The platform integrates with legacy systems and wider application ecosystems, it can ingest any commonly used data source and format, and it can configure and scale for traditional, hybrid, or fully decentralized trials. Recently, Everest Group found that the industry now recognizes the value of a platform-based approach to gain efficiencies in clinical trials and named Oracle a leader in the space.
“FHI Clinical chose Oracle’s Clinical One platform as our default clinical system because it is built the way we would have built for ourselves – single data source, unified platform, intuitive, and cost-efficient,” said Rob King, Chief Operating Officer, FHI Clinical.
New independent studies that compare the performance of Clinical One against industry alternatives reveal its advantages:
“Oracle’s CRO Growth Initiative has elevated Oracle’s commitment to CROs in reducing the barriers to adopting new technology to meet the needs of our customers, all at no risk to us,” said Chems Hachani, CEO ECLEVAR Medtech.
“At Accelsiors, we pride ourselves to provide quality and expertise,” said Philippe Andry, VP Data Management & Data Integration, Accelsiors. “The free enablement and non-production environment for Clinical One has empowered our study build team and data managers to become SMEs in a very short timeframe which allows Accelsiors to deliver successful studies to their sponsors.”
To see Clinical One in action and learn more about the CRO Growth Initiative, visit Oracle Health Sciences February 6-9 at SCOPE 2023 Booth #401.
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.
Oracle, Java, and MySQL are registered trademarks of Oracle Corporation.